Mohr's salt
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Mohr's salt | |
|---|---|
| |
| IUPAC name | Iron(II) ammonium sulfate |
| Other names | Ferrous ammonium sulphate Ammonium iron sulphate |
| Identifiers | |
| CAS number | [10045-89-3] (Anhydrous) [7783-85-9] (Hexahydrate) |
| PubChem | |
| SMILES | [NH4+].[NH4+].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Fe+2] |
| Properties | |
| Molecular formula | FeH20N2O14S2 |
| Molar mass | 392.14 g/mol [hexahydrate] |
| Appearance | Blue-green solid |
| Hazards | |
| MSDS | Fisher MSDS |
| Main hazards | Irritant (Xi) |
| R-phrases | R36/37/38 |
| S-phrases | S24/25 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
|
WikiDoc Resources for Mohr's salt | |
|
Articles | |
|---|---|
|
Most recent articles on Mohr's salt Most cited articles on Mohr's salt | |
|
Media | |
|
Powerpoint slides on Mohr's salt | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Mohr's salt at Clinical Trials.gov Clinical Trials on Mohr's salt at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Mohr's salt
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Mohr's salt Discussion groups on Mohr's salt Patient Handouts on Mohr's salt Directions to Hospitals Treating Mohr's salt Risk calculators and risk factors for Mohr's salt
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Mohr's salt | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Mohr's Salt, or ammonium iron sulfate, is a double salt of iron sulfate and ammonium sulfate, with the formula [NH4]2[Fe][SO4]2·6H2O. Mohr's salt is preferred over iron(II) sulfate for titration purposes as it is much less affected by oxygen in the air than iron(II) sulfate, solutions of which tend to oxidise to iron(III). The oxidation of solutions of iron(II) is very pH dependent, occurring much more readily at high pH. The ammonium ions make solutions of Mohr's salt slightly acidic, which prevents this oxidation from occurring. The relevant equation for this is:
- 4 Fe2+ + O2 + (4+2x) H2O ⇌ 2 Fe2O3.xH2O + 8 H+
The presence of protons keeps this equilibrium to the left, the Fe(II) side.
Mohr's salt is named after the German chemist Karl Friedrich Mohr, who made many important advances in the methodology of titration in the 19th century.
ar:كبريتات أمونيوم حديد ثنائيde:Ammoniumeisen(II)-sulfatfr:Sel de Mohr nl:Mohr's zout
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
